Latest GLMD reports update at 2024-04-27: 2023 ∙ 2022 ∙ 2021

Galmed Pharmaceuticals Ltd. GLMD

$ 0.39 0.9%

Galmed Pharmaceuticals Ltd. Financial Statements 2011-2024 | GLMD

Annual Financial Statements Galmed Pharmaceuticals Ltd.

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	1.16 M	1.34 M	2.36 M	84.7 M	102 M	149 M	63.9 M	46.1 M	69.4 M	67.3 M	-	-	-
Shares	2.77 M	1.68 M	1.64 M	21.3 M	21.1 M	18.1 M	12.5 M	11.4 M	11.1 M	10.3 M	-	-	-
Historical Prices	0.42	0.8	1.44	3.97	4.85	8.24	5.12	5.2	4.61	9.49	-	-	-
Net Income	-6.91 M	-17.9 M	-32.5 M	-28.8 M	-20.5 M	-9.86 M	-12.3 M	-17 M	10.6 M	9.1 M	-17.5 M	-3.15 M	-
Revenue	-	-	-	-	-	2.04 M	1.08 M	467 K	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-30.2 M	-22.4 M	-10.7 M	-12.4 M	-	-	-	-	-	-
Interest Expense	-	-	-414 K	-1.44 M	-1.92 M	934 K	65 K	35 K	-	-	-	-	-
EBITDA	-	-	42 K	-30.2 M	-22.3 M	-10.3 M	-12.1 M	-16.7 M	10.7 M	9.11 M	-14.6 M	-3.13 M	-
Operating Expenses	-	-	32.9 M	-	22.4 M	12.8 M	13.4 M	17.3 M	10.9 M	9.14 M	-	-	-
General and Administrative Expenses	-	-	5.66 M	4.13 M	4.2 M	4.44 M	3.8 M	3.08 M	3.25 M	2.48 M	7.36 M	694 K	-

All numbers in USD currency

Quarterly Income Statement Galmed Pharmaceuticals Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	-	-	25.1 M	-	25.1 M	-	21.3 M	-	21.2 M	-	21.1 M	-	21.1 M	-	21 M	-	15.7 M	-	14.4 M	-	12.2 M	-	12.1 M	-	11.1 M	-	11.1 M	-	11.1 M	-	11.1 M	-	-	-	9.74 K	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-8.4 M	-8.9 M	-	-	-5.53 M	-6.06 M	-	-	-4.17 M	-3.49 M	-	-	-2.68 M	-2.51 M	-	-	-2.69 M	-	-	-	-4.31 M	-	-	-	-2.35 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	270 K	-	-	-	270 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-5.82 M	-	-	-	-4.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	290 K	-	-	-	532 K	-	-	-	90 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-5.82 M	-	-	-	-4.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	8.41 M	-	-	-	5.82 M	-	-	-	4.7 M	-	-	-	2.78 M	-	-	-	2.7 M	-	-	-	4.22 M	-	-	-	2.53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	-	-	-	-	-	1.38 M	-	-	-	845 K	-	-	-	1.21 M	-	-	-	1.1 M	-	-	-	624 K	-	-	-	861 K	-	-	-	967 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency